ABS0710 CAPTURE-JIA PROM (PATIENT-REPORTED OUTCOME MEASURES) AS A TOOL FOR ASSESSING QUALITY OF LIFE IN JIA: DOES IT OFFER US SOMETHING DIFFERENT

Résumé fourni par la source

Background: Assessment of clinical, functional, and quality of life (QoL) outcomes in JIA is essential to understanding the course of the disease and addressing it effectively. Recently, patient-reported outcome measures, such as CAPTURE-JIA PROM (CJP), have been validated. It evaluates three domains (physical, social, and emotional well-being), scored between 0-3, which are inversely proportional to QoL. Objectives: Our objective was to assess the QoL of patients with JIA using CJP, compare it with CHAQ (Childhood Health Assessment Questionnaire), and study which variables influence QoL. Methods: Descriptive and analytical study, ambispective, cross-sectional, in patients under 16 years old with JIA. Participants completed the CJP and CHAQ questionnaires, as well as questions about their socioeconomic status. Clinical and treatment data were collected. A descriptive and bivariate analysis was conducted to assess which variables influenced QoL, and the CJP and CHAQ scores were compared to evaluate their consistency. Results: Fifty-five patients were recruited, whose characteristics are shown in Table 1. CHAQ was directly correlated with CJP for physical, social, and emotional well-being (Rho: 0.477; p<0.001; Rho: 0.351; p=0.009; Rho: 0.282; p=0.033). CJP scores for physical and social well-being showed a positive correlation with the VAS reported by parents (Rho: 0.662; p<0.001; Rho: 0.55; p<0.001) and with cJADAS (Rho: 0.521; p<0.001; Rho: 0.514; p<0.001). The CJP for social well-being showed a positive correlation with JADAS-71 (Rho: 0.491; p=0.038). CJP for emotional well-being was directly related to age (Rho: 0.381; p=0.004) and disease duration (Rho: 0.293; p=0.03). No relationship was found between QoL and the other variables studied. Conclusion: The impact on QoL in our sample is mild. The CJP scale adequately assesses QoL in children with JIA. Physical and social well-being depend on disease control, making remission fundamental. Emotional well-being worsens with age and disease duration, highlighting the need for psychological support during adolescence and in more advanced cases. REFERENCES: [1] Lunt LE, Shoop-Worrall S, Smith N, Cleary G, McDonagh J, Smith AD et al. F. Validation of novel patient-centred juvenile idiopathic arthritis-specific patient-reported outcome and experience measures (PROMs/PREMs). Pediatr Rheumatol Online J. 2020 Nov 19;18(1). [2] McErlane F, Armitt G, Cobb J, Bailey K, Cleary G, Douglas S et al. CAPTURE-JIA: a consensus-derived core dataset to improve clinical care for children and young people with juvenile idiopathic arthritis. Rheumatology (Oxford). 2020 Jan 1;59(1):137-145. Table 1Descriptive Study.Epidemiological VariablesFemale, n (%)32 (58,2)Age (years), me (IQR)10,57 (5,56-12,85)Anthropometric VariablesWeight SD, me (IQR)-0,56 ((-0,93)-0,19)Heigth SE, m (±SD)-0,22 (1,17)BMI SD, me (IQR)-0,44 ((-0,83)- 0,58)Clinical VariablesJIA SubtypePersistent oligoarticular, n(%)29 (52,7)RF-negative polyarticular, n(%)12 (21,8)Psoriatic, n(%)4 (7,3)Systemic, n(%)3 (5,5)Extended oligoarticular, n(%)3 (5,5)ERA, n(%)2 (3,6)Undifferentiated, n(%)2 (3,6)Uveitis, n(%)8 (14,5)Disease duration (years), me (IQR)3,78 (1,81-7,94)Active disease, n(%)13 (23,6)No. of active joints, me (IQR)0 (0-0)Physician VAS, me (IQR)0 (0-0)Parent VAS, me (IQR)0 (0-3)JADAS-71, me (IQR)0 (0-1,9)cJADAS* 1 , me (IQR)1 (0-3)Treatment VariablesNo treatment, n(%)13 (23,6)MethotrexateOral, n(%)22 (40)Subcutaneous, n(%)12 (21,8)Biological DMARDSubcutaneous, n(%)25 (45,5)Intravenous, n(%)2 (3,6)Socioeconomic VariablesNumber of siblings, me (IQR)1 (0-1)Single-parent family, n(%)4 (7,8)Separated parents, n(%)11 (20)Distance from home to hospital (km), me (IQR)18,5 (5-54,75)Own vehicle, n (%)52 (94,5)Sports practice outside school hours, n(%)35 (64,8)Monthly household incomeMore than 5000 euros, n(%)6 (12,2)Between 4000 and 5000 euros, n(%)5 (10,2)Between 3000 and 4000 euros, n(%)7 (14,3)Between 2000 and 3000 euros, n(%)9 (18,4)Between 1000 and 2000 euros, n(%)18 (36,7)Less than 1000 euros, n(%)4 (8,2)Parental education level ⁎2 University, n(%)26 (47,3)Higher vocational training, n(%)8 (14,5)High school, n(%)4 (7,3)Intermediate vocational training, n(%)5 (9,1)Secondary education or lower, n(%)12(21,8)Quality of Life VariablesCAPTURE-JIA PROMSPhysical well-being, me (IQR)1 (1-3)Social well-being, me (IQR)0 (0-1)Emotional well-being, me (IQR)1 (0-1)CHAQ, me (IQR)0 (0-0,38)n: absolute frequency; %: percentage; m: mean; SD: standard deviation; me: median; IQR: interquartile range; VAS: visual analog scale; JADAS-71: Juvenile Arthritis Disease Activity Score (maximum of 71 joints); cJADAS: clinical Juvenile Arthritis Disease Activity Score; DMARD: disease-modifying antirheumatic drug.*1 cJADAS: Score obtained by summing the number of active joints, the physician's VAS, and the patient/family's VAS.*2 The highest educational level of both parents was considered. Acknowledgements: NIL . Disclosure of Interests: Rocío Galindo Zavala Abbvie, Novartis, Abbvie, Pfizer, Pfizer, Novartis, Abbvie, Gisela Diaz-Cordobes: None declared, Laura Martín Pedraz: None declared, Lucia Ramirez Martin: None declared, Maria Ruiz Galdeano: None declared, Esmeralda Núñez Cuadros: None declared. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.